Catalyst Pharmaceuticals

Update in progress

CPRX (NGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for rare diseases in the United States. Its offerings include Firdapse for Lambert-Eaton myasthenic syndrome, Fycompa for focal onset and tonic-clonic seizures, and AGAMREE for Duchenne muscular dystrophy. It has licensing deals with BioMarin and a collaboration with Endo Ventures for generic Sabril. Founded in 2002, based in Coral Gables, Florida.

Company score

Sentiment: 0.17; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.06; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive